Statement Of Investor Complaints For The Quarter Ended 31.03.2017
Statement of investor complaints for the quarter ended 31.03.201720-04-2017
20-04-2017
Outcome of Board Meeting
Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 13, 2017, has :- Decided to grant additional 175243 options to the employees of the Company under ESOP Scheme.Further, the Board meeting commenced on 4.00 p.m. and concluded on 4.50 p.m.13-02-2017
Standalone Financial Results, Limited Review Report for December 31, 2016
Kilitch Drugs India Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 201613-02-2017
Updates on ensuing Board Meeting on Feb 13, 2017
Kilitch Drugs India Ltd has informed BSE that in furtherance of the matters proposed in the Board meeting to be held on February 13, 2017, at the Administrative Office of the Company at Mumbai at 4.00 P.M., for which the intimation was already given, the following additional matter is also proposed to be discussed and considered:- To consider grant of additional options to the employees of the Company under ESOP Scheme.09-02-2017
Board Meeting Intimation for Results & Closure of Trading Window
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 13, 2017, inter alia, to consider and take on record the following matters:- Unaudited (Provisional) Financial Result for the quarter ended December 31, 2016 along with the Limited Review Report as submitted by the Statutory Auditors of the Company....02-02-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Kilitch Drugs India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.22-01-2017
Shareholding for the Period Ended December 31, 2016
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here21-01-2017
Outcome of Board Meeting
Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 14, 2016, has transacted the following:- Accepted the resignation tendered by Mr. Deepu Panankattil as the Director of the Company w.e.f November 30, 2016.Further, the Board meeting commenced on 3.00 p.m. and concluded on 3.50 p.m.14-11-2016
Standalone Financial Results, Limited Review Report for September 30, 2016
Kilitch Drugs India Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 201614-11-2016
Board Meeting Intimation for Results & Closure of Trading Window
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 14, 2016,inter alia, to consider and take on record the following matters.- Unaudited (Provisional) Financial Result for the quarter and half year ended September 30, 2016 along with the Limited Review Report as submitted by the Statutory Auditors of the Company....04-11-2016